Gastroprotected Superoxide Dismutase in Combination With UVB vs Placebo and UVB for Treating Vitiligo.
NCT ID: NCT03941808
Last Updated: 2022-08-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
50 participants
INTERVENTIONAL
2019-06-17
2020-12-01
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Adult patients with non-segmental vitiligo affecting more than 5% of body surface area will be included.
The main criteria of evaluation will be the VES score at 6 months compared to baseline in both groups.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Oral Superoxide Dismutase (GLISODin) to Decrease Melasma Severity.
NCT03878433
Oral Ginkgo Biloba and Narrow Band UVB in the Treatment of Vitiligo
NCT01006421
Combination Approach With Ritlecitinib and nbUVB Compared to Ritlecitinib Alone for Treating Vitiligo
NCT07152626
A Clinical Study of MK-6194 for the Treatment of Vitiligo (MK-6194-007)
NCT06113328
A Study to Evaluate the Safety and Efficacy of Ruxolitinib Cream With Phototherapy in Participants With Vitiligo
NCT05247489
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
DOUBLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Drug
4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Glisodin tablet
4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Placebo
4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Placebo tablet
4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Glisodin tablet
4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Placebo tablet
4 pills a day (1000mg) for 3 months then 2 pills a day (500 mg) for 3 months
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Vitiligo, SOD, UVB
* Non-segmental vitiligo with BSA\>5%
Exclusion Criteria
* Segmental or mixed vitiligo
* Pregnancy
* Vitiligo lesions localized only on hands and feet
* Immuno-suppressive drugs
* Corticosteroids
* Photosensitive drugs
* Photodermatosis
* Personal history of skin cancer
* Allergy to gluten
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Centre Hospitalier Universitaire de Nice
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Passeron Thierry, PhD
Role: PRINCIPAL_INVESTIGATOR
Centre Hospitalier Universitaire de Nice
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Passeron
Nice, Alpes-Maritime, France
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
19-PP-01
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.